Clinical Edge Journal Scan

RA raises risk for long-term MACE in patients undergoing percutaneous coronary intervention


 

Key clinical point: Rheumatoid arthritis (RA) reduced survival rates and increased the risk for long-term major adverse cardiovascular events (MACE) in patients with ischemic heart disease who underwent percutaneous coronary intervention (PCI); however, RA had no influence over short-term MACE.

Major finding: Patients with vs without RA who underwent PCI had lower survival rates (log-rank P < .001) and were at a significantly higher risk for long-term MACE (adjusted hazard ratio 1.07; P < .001), although the risk for short-term MACE was not significantly different between both the cohorts ( P = .222).

Study details: This retrospective cohort study included 236,134 patients who underwent PCI, of which 34,493 patients had RA.

Disclosures: This study was supported by the Medical Research Promotion Program of Gangneung Asan Hospital, funded by the Asan Foundation, South Korea. The authors declared no conflicts of interest.

Source: Ha SJ et al. Clinical outcomes of patients with rheumatoid arthritis who underwent percutaneous coronary intervention: A Korean nationwide cohort study. PLoS One . 2023;18(2):e0281067 (Feb 14). Doi: 10.1371/journal.pone.0281067

Recommended Reading

What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
MDedge Rheumatology
Bacteremia, antibodies link periodontal disease to RA development and activity
MDedge Rheumatology
FDA approves first biologic treatment for polymyalgia rheumatica
MDedge Rheumatology
Commentary: ILD and other issues in RA treatment, March 2023
MDedge Rheumatology
Call it preclinical or subclinical, ILD in RA needs to be tracked
MDedge Rheumatology
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatology
MDedge Rheumatology
New JAK inhibitor study data confirm benefit in alopecia areata
MDedge Rheumatology
Tofacitinib may have possible protective effect against ILD in RA
MDedge Rheumatology
Administering concomitant methotrexate at a half vs usual dose while initiating TNFi is feasible
MDedge Rheumatology
Higher disability at early stages raises risk for progression to difficult-to-treat RA
MDedge Rheumatology